-
NICE launches refreshed support service for life sciences industry
NICE has launched its refreshed support service for the life sciences sector, NICE Advice.
-
NICE launches first modular update to its methods and processes
NICE’s methods and processes now include a proportionate approach to technology appraisals, and a new way of updating recommendations on COVID-19 treatments.
-
First NICE-recommended treatment for Parkinson’s set to benefit hundreds
Around 900 adults with advanced Parkinson’s are set to benefit from new treatment foslevodopa–foscarbidopa after NICE approved it for NHS use in final draft guidance published today (26 October 2023).
-
People who have had a stroke should be offered additional rehabilitation to help them recover NICE says in updated guidance
People who have had a stroke and who have continuing impairment or limitations on their activities should be offered additional rehabilitation to help them recover, NICE has said in updated guidance published today.
-
First treatment to be recommended by NICE at the same time it is approved for advanced lymphoma in the UK
More than 700 people set to benefit from new treatment option for advanced lymphoma.
-
Seven technologies recommended to help people with non-specific low back pain
People with low back pain could be offered apps to help them manage their condition after seven digital technologies were recommended by NICE in draft guidance.
-
NICE recommends healthcare professionals ask people about gambling, in new draft guidance out for consultation
New NICE draft guidance on identifying, assessing and managing harmful gambling published
-
NICE says non-invasive weight loss procedure can be an option to treat obesity
A procedure which reduces the size of the stomach by two-thirds to help people living with obesity to lose weight has been deemed safe and effective to be used in the NHS, NICE has said.
-
NICE draft guidance recognises potential of new targeted treatment for type of advanced breast cancer
NICE has today (26 September 2023) published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for treating advanced HER2-low breast cancer in adults.